A study, conducted by UC Davis Comprehensive Cancer Center researchers, shows an alarming number of California women 65 and older are facing late-stage cervical cancer diagnoses and dying from the disease, despite guidelines that recommend most women stop screening for cervical cancer at this age.
Citius Oncology announced positive topline results from a completed investigator‑initiated phase I clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory cell depletion activity of Lymphir (denileukin diftitox‑cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.
